MyBiotics
Jerusalem, Israel· Est.
Israeli microbiome biotech delivering AI‑enhanced live bacterial therapeutics for gut‑related diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $5M
AI Company Overview
Israeli microbiome biotech delivering AI‑enhanced live bacterial therapeutics for gut‑related diseases.
Infectious DiseasesGastroenterologyOncologyWomen's Health
Technology Platform
MyCrobe™ single‑strain fermentation, SuperDonor™ whole‑microbiome recovery, and SuperDonor Select™ designer consortia, all integrated with AI‑driven discovery and formulation pipelines.
Opportunities
Leveraging AI‑enhanced microbiome design to accelerate pipeline progression and expanding into high‑value oncology and reproductive‑medicine indications.
Risk Factors
Regulatory uncertainty for live biotherapeutics, scale‑up manufacturing challenges, and intense competition from established microbiome firms.
Competitive Landscape
Competes with Seres Therapeutics, Finch Therapeutics, and Vedanta Biosciences; differentiation stems from its artificial donor bank, non‑GMO strains, and AI‑driven consortia design.